Porphyrin-Based Tumor-Targeting Theranostic Agent: Gd-TDAP.

ABSTRACT: The aim of this work was to evaluate a tumor-targeting porphyrin-based gadolinium complex (Gd-TDAP) for use as an MR/optical imaging agent and potential therapeutic agent. Gd-TDAP had higher longitudinal relaxivity (11.8 mM^-1 s^-1) than a commercial MRI contrast agent (Omniscan; 3.7 mM^-1 s^-1) in HSA solution (0.67 mM) at 3 T. The tumor-targeting characteristics were confirmed by T₁-weighted MR imaging and optical imaging using an orthotopic brain tumor mouse model, which showed 1.3-fold higher uptake in tumor compared to normal brain tissues. The cell fraction data using U87MG glioblastoma cells indicated the potential for gadolinium neutron capture therapy (Gd-NCT), which requires gadolinium to be inside the cell nucleus. In addition,

SUBMITTER: Kim S 

PROVIDER: S-EPMC8436409 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature